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A B S T R A C T
Background AML1/RUNX1 is the most frequently mutated gene in leukaemia and is central to the normal biology of hematopoietic stem and progenitor cells. However, the role of different AML1 isoforms within these primitive compartments is unclear. Here we investigate whether altering relative expression of AML1 isoforms impacts the balance between cell self-renewal and differentiation in vitro and in vivo.
Methods and Findings
The human AML1a isoform encodes a truncated molecule with DNA-binding but no transactivation capacity. We used a retrovirus-based approach to transduce AML1a into primitive haematopoietic cells isolated from the mouse. We observed that enforced AML1a expression increased the competitive engraftment potential of murine long-term reconstituting stem cells with the proportion of AML1a-expressing cells increasing over time in both primary and secondary recipients. Furthermore, AML1a expression dramatically increased primitive and committed progenitor activity in engrafted animals as assessed by long-term culture, cobblestone formation, and colony assays. In contrast, expression of the full-length isoform AML1b abrogated engraftment potential. In vitro, AML1b promoted differentiation while AML1a promoted proliferation of progenitors capable of short-term lymphomyeloid engraftment. Consistent with these findings, the relative abundance of AML1a was highest in the primitive stem/progenitor compartment of human cord blood, and forced expression of AML1a in these cells enhanced maintenance of primitive potential both in vitro and in vivo.
Conclusions
These data demonstrate that the ''a'' isoform of AML1 has the capacity to potentiate stem and progenitor cell engraftment, both of which are required for successful clinical transplantation. This activity is consistent with its expression pattern in both normal and leukaemic cells. Manipulating the balance of AML1 isoform expression may offer novel therapeutic strategies, exploitable in the contexts of leukaemia and also in cord blood transplantation in adults, in whom stem and progenitor cell numbers are often limiting.
Introduction AML1 (also termed RUNX1 or CBFA2), which encodes a transcription factor, was originally identified as a component of the fusion gene generated as a consequence of the t(8; 21) chromosomal translocation characteristic of a subset of acute myelogenous leukaemia [1] . Subsequently, mutations in the AML1 gene were shown to be associated with a number of malignant and premalignant conditions including acute myelogenous leukaemia , childhood acute lymphocytic leukaemia, familial platelet disorder, and myelodysplastic syndromes. AML1 is thus the most frequently mutated gene in human leukaemia [2, 3] . Aml1 expression marks long-term repopulating hematopoietic stem cells (HSCs) in the midgestation mouse embryo [4] , and gene targeting experiments have unequivocally shown Aml1 to be essential for the development of the hematopoietic system; Aml1-null mice die in utero of haemorrhage and lack adult-type hematopoiesis because of a failure in the generation of definitive HSCs [5, 6] . In contrast, conditional gene-targeting experiments have revealed that Aml1 is dispensable for maintenance of adult HSCs. Aml1 deficiency in adult stages is accompanied by increases in myeloid progenitors and phenotypically defined HSCs, as well as impaired development of lymphoid and megakaryocytic cells [7] [8] [9] .
While AML1 is known to regulate the expression of many hematopoietic genes, including those encoding cytokines and their receptors as well as other transcription factors, the full spectrum of its target genes in different cell types in normal hematopoiesis, or AML1-associated leukaemia, remains unknown [10, 11] . Furthermore, the manner in which AML1 is itself regulated at the level of transcription and posttranscriptional processing is largely not understood [12] . Addressing these issues will be essential to understanding how AML1 plays such a crucial role in both normal and leukaemic hematopoiesis. Potentially confounding factors in these endeavours are the large size of the AML1 locus, the complexity of its putative regulatory elements, and the prevalence within the AML1 gene of extensive alternative splicing [13] [14] [15] .
Evidence is accumulating that isoforms of key hematopoietic transcription factors can play both distinct and key regulatory roles in hematopoiesis. A case in point is GATA1, which regulates the differentiation of erythroid and megakaryocytic cells [16] . Full-length GATA1 is composed of an amino-terminal transactivation domain as well as two zinc fingers that mediate its binding to DNA. However, an isoform lacking the transactivation domain is also expressed. This short form is impaired in its ability to promote differentiation and is implicated in abnormal hematopoiesis associated with Down syndrome [17, 18] . Similarly, truncated forms of SCL/TAL1 favour erythroid lineage development, whereas full-length forms enhance the development of the megakaryocytic lineage [19] . An alternatively spliced isoform of TEL/ETV6 has recently been shown to inhibit, in a dominant-negative manner, the activity of full-length TEL and thereby negatively regulate the TEL-mediated erythroid differentiation of mouse erythroleukaemia cells [20] . Finally, enforced expression of an isoform of IKAROS/IKZF (IKAROS 6), which lacks the DNA-binding domain, in human CD34 þ cells limits B cell development [21] . IKAROS isoforms are also implicated in the development of leukaemia [22] [23] [24] .
The human AML1 gene generates three alternatively spliced variants, AML1a, AML1b, and AML1c [25] . AML1b and AML1c both possess the DNA-binding region (runt domain) at the amino-terminal end as well as the carboxylterminal transcriptional regulatory domains; AML1b and AML1c are therefore considered to be broadly similar in function. In contrast, AML1a retains the DNA-binding domain, but lacks the transcriptional regulatory domains. AML1a is thus considered a potential functional antagonist of AML1b and AML1c [25] . The opposing functions of AML1a and AML1b have been shown in myeloid-committed cell lines with respect to their granulocyte colony-stimulating factor (G-CSF)-induced differentiation programmes; ectopically expressed AML1a blocks granulocytic differentiation, and this blockade is released by enforced expression of AML1b. Differentiation arrest in this cell-line model is accompanied by uncompromised growth under culture conditions that normally induce differentiation in the parental cell line [26] . AML1a transcripts have also been noted in selected leukaemia samples, as have mutant truncated forms of the AML1 protein that structurally resemble AML1a [26] [27] [28] [29] . However, little is known about the potentially differential roles of AML1 isoforms in regulating normal or leukaemic cell fates in the stem and progenitor compartment of hematopoiesis. To address these questions, we expressed AML1a and AML1b in primary murine bone marrow (BM)-derived hematopoietic stem/progenitor cells and analysed the resulting effects on hematopoiesis both in vitro and in vivo. We then performed similar experiments in the corresponding human compartments. Such studies may lead to new strategies for the manipulation of haematopoietic progenitors and inform future treatments for haematological malignancies
Methods

Generation of Retroviruses
cDNAs for AML1a and AML1b [25] (generous gifts of Misao Ohki, National Cancer Center, http://www.ncc.go.jp) tagged with the FLAG-epitope at the amino terminal were cloned upstream of the internal ribosome entry site (IRES) element into the EcoRI/XhoI restriction site of the murine stem cell virus-internal ribosome entry site-green fluorescent protein (GFP) vector (MSCV-IRES-GFP) [30] . The MSCV-IRES-human CD4 vector that expresses an extracellular portion of the human CD4 molecule was generously provided by Jason G. Cyster (University of California San Francisco, http://www. ucsf.edu) [31] . Retrovirus vector plasmids were transiently transfected into Phoenix-Eco packaging cells (obtained from American Type Culture Collection, http://www.atcc.org) by a standard calcium phosphate precipitation method. Virus supernatants were then concentrated by centrifugation before use in infecting cells [32] .
Retroviral Infection of Mouse BM Cells and Transplantation
BM cells were harvested from tibiae and femora of BALB/c mice 4 d after intravenous administration of 5-fluorouracil (5-FU) (150 mg/kg) and treated with ACK (0.15 M NH 4 Cl, 1.0 mM KHCO 3 , 0.1 mM EDTA) to lyse red blood cells. BM cells were then prestimulated with stem cell factor (SCF) (100 ng/ ml) þ interleukin (IL) 3 (IL3) (10 ng/ml) þ IL6 (6 ng/ml) (Peprotech, http://www.peprotech.com) for 24 h and spin-infected with concentrated virus in the presence of cytokines and polybrene (4 lg/ml) (Sigma, http://www.sigmaaldrich.com) [32] . Cells (1 3 10 6 ) were transplanted intravenously into lethally irradiated (7.5 Gy) recipient mice, which were maintained on acidified water throughout the experimental period [32] . In some experiments, lin
progenitor cells sorted from C57BL6 mice were used, in place of 5-FU-treated BM cells. Results obtained using the two different sources of cells were essentially identical. For competitive repopulation, BM cells from the 5-FU-treated mice were infected with retroviruses for either GFP only, AML1a, or human CD4. Cells were then admixed to obtain mixtures of GFP-transduced and CD4-transduced cells, or AML1a-transduced and CD4-transduced cells for transplantation.
Flow Cytometry of Mouse Cells
After red blood cell lysis, cells were incubated with the indicated antibodies, conjugated with either one of phycoerythrin, biotin, or allophyocyanin (APC); biotinylated antibodies were then stained with streptavidin-APC or streptavidin-peridinin-chlorophyll-protein Cy5.5. Nonspecific binding was blocked by preincubation with an anti-Fc receptor antibody (2.4G2). Antibodies used were as follows: anti-CD3 (145-2C11), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-B220 (RA3-6B2), anti-CD19 (1D3 and MB19-1), anti-TER-119 (TER-119), anti-Gr-1 (RB6-8C5), anti-Mac-1 (M1/70), anti-c-kit (2B8), anti-CD34 (RAM34), anti-Sca-1 (D7), and anti-human CD4 (RPA-4). Isotype-matched Ig was used as a control. Antibodies were obtained from BD Biosciences (http://www.bdbiosciences.com) and eBioscience (http://www. ebioscience.com). Cells were washed with PBS containing 1% fetal calf serum and analysed on a FACSCalibur (BD Biosciences) with CELLQUEST software. Cell sorting was conducted with a FACSVantage (BD Biosciences).
Western Blot Analysis
Total cell lysates were fractionated by SDS-PAGE and blotted onto a nylon membrane. AML1a and AML1b were detected with an anti-AML1 antibody (Ab-2, Oncogene Research Products, http://www.merckbiosciences.co.uk) or an anti-FLAG antibody (M2, Sigma). Anti-tubulin antibody (Sigma) was used to allow comparison of loaded protein amounts. Primary staining was visualized with a goat antirabbit Ig-horseradish peroxidase (HRP) conjugate, a goat anti-mouse Ig-HRP conjugate, or a secondary antibody by using enhanced chemiluminescence (Amersham Bioscience, http://www.amersham.com). Western blot analysis of primary human cord blood was conducted using a 12% acrylamide gel, and the AML1 proteins were detected using an anti-AML1 antibody (Ab-2) in combination with the highly sensitive West Femt reagent (Pierce, http://www.piercenet. com). were typed and counted at day 7. For colony-forming unit (CFU) megakaryocyte (meg) (CFU-meg), a-MEM supplemented with 0.8% methylcellulose, 1% BSA, 30% FBS, 0.1 mM 2-mercaptoethanol, and 10 units of mouse thrombopoietin (Peprotech) was used [7] .
In Vitro Colony-Forming Assays of Mouse Cells
In Vitro Culture of Mouse Cells
Transduced cells were maintained in Iscove's modified Dulbecco's medium (Gibco, http://www.invitrogen.com) supplemented with 10% fetal calf serum in the presence of SCF (50 ng/ml) and IL3 (10 ng/ml). Cytokines were purchased from Peprotech.
Cell-Cycle Analysis
Cells in culture were incubated with 10 lM of 5-bromo- 29 (50 ng/ml), IL3 (20 ng/ml), and IL6 (20 ng/ml) for 7 d and isolated using a CD36-PE antibody in combination with anti-PE magnetic beads [33] . The resulting cells gave 98% erythroid output when plated in methylcellulose containing SCF, IL3, IL6, GM-CSF, G-CSF, and Epo.
Quantification of AML1 Isoforms in Human Cord Blood by Reverse Transcription-PCR
Primers 59-GAGGGAAAAGCTTCACTCTGA-39 (primer C), GTGTACCGGGATCCATGCTA-39 (primer 3A), and 59-GTTGAGAGTCGACTGGAAAG-39 (primer 2B) were used to detect AML1a (primers C and 3A) and AML1b/AML1c (primers C and 2B) as described [25] . PCR products thus obtained were then used as templates for additional PCR with the following primer sets to generate competitor DNAs: 59-TTTGAATTC-GAGGGAAAAGCTTCACTCTGAGAACCTCGAAGA-CATCGGCA-39 (primer C9), 59-TTTGAATTCGTGTACCGG-G A T C C A T G C T A -3 9 ( p r i m e r 3 A 9) , a n d 5 9-TTTGAATTCGTTGAGAGTCGACTGGAAAG-39 (primer 2B9). These primer sets were designed to generate products 157 bp shorter than the authentic PCR products and to facilitate subcloning. PCR products with primers C9 and 3A9, or with primers C9 and 2B9, were digested with EcoRI, and inserted into the EcoRI site of the pBluescript vector (Stratagene, http://www.stratagene.com) to obtain pBS/competitor A and pBS/competitor B. NotI/XhoI fragment of pBS competitor A was then inserted into NotI/XhoI site of the pMXs vector, then the EcoRV/XhoI fragment was inserted into the EcoRV/XhoI site of the pBS/competitor B. The plasmid thus obtained (pBS/competitor A þ B) contained competitors for AML1a and AML1b in back-to-back orientation, with 1,250 bp of intervening spacer. This pBS/ competitor A þ B was used for the competitive PCR for both AML1a and AML1b/AML1c to quantitate AML1 isoforms in a given cell population [34] . Total RNA was isolated from the fractionated cord blood cells using Trizol reagent (Invitrogen, http://www.invitrogen.com) and then reverse-transcribed using random primers and Superscript II enzyme according to the manufacturers' instructions. cDNA thus obtained was then mixed with known amounts of the competitor plasmid and PCR was conducted either with primer sets C and 3A, or with primer sets C and 2B. PCR products were then fractionated on a 2.5% agarose gel electrophoresis, and the PCR products from endogenous AML1 and from the competitor plasmid were quantitated densitometrically. The amounts of the endogenous AML1 isoforms were then estimated as described [34] and normalized on the basis of G6PD expression estimated by a quantitative real-time PCR [35] .
Preparation of Lentivirus and Cord Blood Cell Transduction
An AML1a cDNA was cloned into the pHR-SINCSGW lentivirus [36] , which carries an emerald-GFP reporter. Lentiviruses were pseudotyped with the vesicular stomatitis virus G (VSVG) protein by transient transfection of 293T cells. High-titre viral stocks were prepared by ultracentrifugation [37] . CD34-enriched cord blood cells were infected for 24 h by lentivirus (either AML1a or control virus) with MOI of 100 in serum free medium Stem/Span (Stem Cell Technologies) supplemented with SCF (100 ng/ml), FLT-3 ligand (100 ng/ml), thrombopoietin (20 ng/ml), and IL6 (20 ng/ml) (all growth factors were from Peprotech) [38, 39] .
In Vitro Analysis of Human Cells
Colony-forming cell (CFC) assays with human cells were under serum-free conditions with recombinant human SCF, GM-CSF, IL3, IL6, G-CSF, and Epo (MethoCult H4536, StemCell Technologies). LTC-IC assays with human cells were performed in 96-well format in Myelocult H5100 medium (StemCell Technologies) on a feeder layer comprising a 1:1 mixture of irradiated M210B4 and S1/S1 mouse fibroblasts [40] . For limiting dilution CAFC assays MS-5 stroma cells [41] were maintained in a-MEM medium complemented with 2 mM L-glutamine, 2 mM sodium pyruvate, 10% FBS (Stem Cell Technologies). After the cells were inoculated, weekly half medium changes were performed for the duration of the culture. CFAC were scored at 6 wk [42, 43] .
Nonobese Diabetic-Severe Combined Immunodeficient Mice and Transplantations
Nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice were bred and maintained at the Weatherall Institute of Molecular Medicine (WIMM) animal facility in accordance with Home Office regulations (United Kingdom). Animals were handled under sterile conditions. Transplantations were performed by tail-vein or intrafemoral injection into 6-to 10-wk-old mice. Recipients received 350 cGy of total body irradiation, and BM engraftment was assessed at 8 wk post-transplantation. Human cell engraftment was assessed by staining of BM cells with anti-CD19-APC (DAKO), anti-CD34-PE (BD Biosciences Pharmingen), anti-CD45-APC (DAKO, http://www.dako.com), and CD38-FITC (DAKO). and expression of AML1a and AML1b were confirmed by Western blotting using an antibody directed against a peptide within the AML1 runt domain ( Figure 1C ), which also detects endogenous murine Aml1; the identity of the AML1a and AML1b were additionally confirmed by Western blotting with an antibody directed against the FLAG tag ( Figure 1C ). These results also showed that the expression level of exogenous AML1a and AML1b was less than 2-fold that of endogenous Aml1 in the cells used subsequently for transplantation. Animals were transplanted in cohorts to facilitate kinetic studies of engraftment ( Table 1 ). The contribution of control vector-transduced cells was relatively stable over time in all cohorts followed. AML1b-transduced cells, in contrast, never contributed to BM at 1 mo or thereafter. Strikingly, the contribution of AML1a-transduced cells increased with time; in a typical case (cohort 4), percentage GFP was 10.5% at 3.5 mo, 11.4% at 4 mo, 42.2% at 11.5 mo, and 53.4% at 12 mo. Western blotting showed that exogenous AML1a expression was 2-to 3-fold higher than endogenous Aml1 and confined exclusively to GFP þ cells within the graft ( Figure 1D ). These results suggest that while AML1b expression abrogates engraftment potential, AML1a expression confers a growth advantage on BM cells in vivo.
Results
Effects of AML1a and AML1b on Long-Term Engrafting Cells and Hematopoiesis In Vivo
We therefore examined this growth advantage using competitive repopulation assays. Competitor cells marked by expression of the extracellular domain of a human CD4 were mixed with either AML1a-or control vector-transduced cells just prior to transplantation into cohorts of lethally irradiated mice. In one cohort, a mixture of 6.2% of GFP Figure 1E -revealed the engraftment potential of AML1a-expressing cells to be substantially higher than their control-vector transduced counterparts. Kinetic studies conducted over a 9-mo period (Table 2) showed the ratio of GFP and CD4 to be relatively stable in the control-vector/CD4 cohort. In contrast, the GFP/ CD4 ratio increased with time in the AML1a/CD4 mice cohort (Table 2 ). This property was also evident in the secondary transplantation experiments: when BM cells from a primary recipient exhibiting GFP/CD4 ratio ¼ 1.6 at 3 mo posttransplant were secondarily transplanted, the secondary recipients displayed ratios of 3.0 6 1.41 (mean 6 standard deviation) at 3 mo and 9.0 6 3.29 at 8 mo post-transplant. This increase in the GFP/CD4 ratio was not seen in mice secondarily transplanted with BM cells taken from control (control-vector/CD4) cohorts. Collectively, these results suggest that expression of AML1a confers a high level of competitive engraftment potential.
We explored this competitive potential further by examining the status of the primitive progenitor compartment in primary AML1a recipients. We determined the number of cKit We next examined the committed progenitor compartment using CFC assays. GFP þ cells from AML1a mice displayed increased total CFC activity ( Figure 2D ) primarily in granulocyte-and/or macrophage-restricted (CFU-GM) and primitive mixed lineage (CFU-mix) progenitors. Furthermore, AML1a-expressing colonies (GFP þ ) were larger than those produced from control cells (GFP À ) from the same animals ( Figure 2E ). AML1a expression did not alter the frequency of erythroid colonies (erythropoietic burst formation) generated but was associated with an increase in CFU-meg formation ( Figure 2D ), but cells in these CFU-meg colonies were smaller than controls, displaying hypolobulated nuclei indicative of impaired differentiation (unpublished data). Consistent with these CFC data, the lin À c-kit þ progenitor compartment was increased 4.0-fold in the GFP þ versus GFP À fraction in animals transplanted with AML1a-transduced BM, and these animals also displayed increases in immature blast-like cells ( Figure S1 ). Morphological exami- 
BM cells from 5-FU-treated mice were transduced with the AML1a-or AML1b-containing and GFP-only control retrovirus and transplanted into cohorts of lethally irradiated syngeneic hosts to allow analysis of engraftment over time. The table shows Ratios of cells expressing human CD4 and GFP just before transplantation were 1.6 for a mixture of GFP-only control and human CD4-transduced cells and 0.79 for a mixture of AMLa-and human CD4-transduced cells. Cells were transplanted into nine mice each, and then three mice each were sacrificed 3, 6, and 9 mo after transplantation. Ratios of GFP/hCD4 were analysed by flow cytometry as shown in Figure 2 , and the median and range in each of the three mice are presented. The GFP/CD4 ratios were not statistically different at any time of analysis for GFP-only control, but AML1a/CD4 ratios increased with time (p , 0.01; nonparametric trend test). BM cells taken from mice 3 mo after primary transplantation (above) were then used for secondary transplantation. BM cells from mice showing GFP-only control/hCD4 ratios 1.6 and 1.7 were transplanted into six mice each. Mice were then sacrificed 3 and 8 mo after the secondary transplantation and analysed for GFP/hCD4 ratios. The ratios were not different between 3 and 8 mo. Similarly, BM cells from mice showing AML1a/hCD4 ratios 1.6 and 1.4 were transplanted into six mice each, and expressions of GFP and hCD4 were analysed 3 and 8 mo later. In this case again, the AML1a/hCD4 ratios increased over time (p , 0.05; nonparametric trend test). N.S., not significant. doi:10.1371/journal.pmed.0040172.t002 Figure S1A ), which was confirmed by immunophenotyping (unpublished data). There were no morphological or immunophenotypic indications of arrested differentiation in the AML1a-expressing myeloid compartment ( Figure S1B and S1C).
AML1a and AML1b Display Opposing Effects on Myeloid Differentiation In Vitro
The abrogation of engraftment by AMLb precluded further analysis of its effects on haematopoietic cells in vivo. We therefore compared effects of AMLb and AML1a on the clonogenic activity of appropriately transduced 5-FU cells (see Figure 1A and 1B) in vitro using CFU in culture assays. The total number of colonies was similar in AML1a-and control vector-transduced cells, but significantly reduced in AML1b-expressing cells ( Figure 3A) . Upon serial replatingan assay of self-renewal-AML1b-expressing cells gave rise to significantly fewer colonies than control vector-transduced cells at all passages examined, whereas expression of AML1a produced more colonies. Furthermore, compared with colonies produced by control vector-transduced cells, colonies from AML1a-expressing cells were larger, whereas colonies from AML1b-expressing cells were smaller ( Figure  S2A ). Analysis of cell-cycle status, as assessed by using BrdU incorporation and DNA content, revealed that AML1a-expressing cells were more proliferative than controls or AML1b-expressing cells ( Figure 3B and 3C) . Results of colony typing and morphological assessment of cells within primary colonies are shown in Figure 3D . AML1b-expressing cells produced no erythroid output and gave rise to significantly more granulocyte-restricted CFU (CFU-G) than control cells. The overall distribution of colony type produced by AML1a-expressing cells was similar to that seen in controls, but the granulocytic component within CFU-GM colonies was markedly decreased (unpublished data). AML1b-expressing cells did not produce CFU-meg colonies ( Figure 3E ). In contrast, AML1a cells produced more CFU-meg than controls ( Figure  3E ). When compared with vector-transduced control cells, the Gr-1-high mature granulocytic fraction was increased by AML1b expression and decreased by AML1a expression in both multimyeloid and myelomonocytic conditions. However, upon replating, AML1a-expressing cells started to express high levels of Gr-1 ( Figure 3F ), which was accompanied by the appearance of morphologically mature granulocytes ( Figure 3G ). Similar results were obtained when cells were plated under myelomonocytic-(SCF þ IL3 þ IL6 þ GM-CSF) promoting culture conditions (unpublished data).
Collectively, these findings suggest that AML1b expression promotes granulocytic differentiation at the expense of alternative lineages, and AML1a expression retards but does not block granulocytic maturation of BM cells under the conditions used while promoting self-renewal and proliferation of progenitor cells. Furthermore, AML1a-transduced cells recovered from the third round of replating propagated in suspension culture, displaying a cumulative cell expansion of about 10 14 -fold in 9 wk ( Figure 4A ). The cultures comprised an adherent layer of macrophages and a mixture of floating monocytic, granulocytic, and blast-like cells ( Figure S2B ). These cultures were reproducibly established in both BALB/c and C57BL6-derived cells and continued to express exogenous AML1a as evidenced by Western blotting with anti-RHD and anti-FLAG antibodies ( Figure 4B Collectively, these data suggest that AML1a expression maintains short-term reconstituting multipotent progenitors prolonged in vitro culture.
Analysis of AML1 Isoforms in Human Cord Blood
Taken together, the data obtained in mouse cells raised the possibility that AML1 may have some utility in the setting of expansion of human cord blood-derived stem and progenitor cells. We therefore next assessed the expression of AML1 isoforms in different cellular compartments of human cord blood, which is a rich source of stem and progenitor cells. For these experiments a quantitative competitive reverse transcription-PCR strategy was used (see Methods). Total AML1 (AML1a þ AML1b/c) expression was similar in progenitor (CD34 Figure 5C ). These expression data, particularly the protein data, raise the possibility that expression of AML1a may be relevant to the function of primitive human haematopoietic cell compartments. We explored this possibility functionally by constructing a lentiviral expression vector for AML1a ( Figure 6A ), using it to transduce CB cells, and subsequently assessed their behaviour in vitro and in vivo. AML1a lentivirus-transduced CD34 Consistent with this, functional assessment of primitive cell activity within the GFP þ and GFP À fractions of the graft using LTC-IC assays revealed a 3-fold increase in the GFP þ (i.e., AML1a-expressing) population ( Figure 6F ). Taken together, these results indicate that AML1a has the capacity to enhance primitive hematopoietic cell function in human cord blood both in vitro and in vivo.
Discussion
Here, we show that AML1a increases the competitive engraftment potential and in vitro proliferation capacity of primitive BM compartments, while AML1b exhibits an essentially opposing activity, promoting differentiation and abrogating engraftment. Expression of AML1a in human cord blood-derived hematopoietic cells gave results broadly in line with those obtained in mouse cells.
Although AML1/RUNX1 has been shown to be critically involved in the generation and maintenance of hematopoietic stem and progenitor cells as well as the differentiation of their progeny, the precise roles of its different isoforms in these processes is not as yet fully understood [44, 45] . Most studies have focused on the role of Aml1 in the specification of HSC either in knockout mice or using the hematopoietic differentiation of embryonic stem cells as a model [46] [47] [48] . These studies indicate that expression of Aml1b or an Aml1b molecule that lack its carboxyl-terminal (VPRWY) repression domain is sufficient to rescue definitive hematopoiesis in Aml1-deficient cells or animals. In contrast AML1 moieties that lack the transactivation domain, and hence may be considered AML1a-like, are unable to rescue hematopoiesis. Elegant as these studies are they do not directly address the physiological role of AML1a in homeostatic adult hematopoiesis, its potential as a nonphysiological but therapeutic regulator of the adult stem and progenitor compartment, nor its pathological activity in leukaemia. Here we have approached these issues and provided evidence that the AML1a and AML1b isoforms have opposing effects on hematopoietic stem and progenitor cells. Most notably, in murine cells we have shown that expression of AML1b abrogates hematopoietic reconstitution in an experimental transplant setting, whereas expression of AML1a significantly enhances competitive engraftment potential in both primary and secondary recipients. In mice transplanted with AML1a-transduced cells, the frequency of primitive progenitors was significantly enlarged. CAFC activity was increased 14-fold relative to controls, and the frequency of LTC-IC in the lin À compartment increased 4-fold; since the lin À compartment was itself more than 3-fold increased, the overall increase in total LTC-IC was at least 12-fold in AML1a-transduced versus untransduced cells. Committed progenitor activity (as judged by CFC assays) in the AML1a-expressing component of the grafts was also increased, but to a lesser degree, and the colonies produced were larger, suggesting increased prolif- eration, but they exhibited no block in myeloid differentiation. Since AML1b abrogated engraftment, further comparison with AML1a was necessarily conducted in vitro. Here AML1b promoted granulocytic differentiation whereas AML1a enhanced self-renewal as judged by colony replating and gave rise to larger colonies, which were somewhat retarded, although not arrested, in granulocyte differentiation.
Cell-cycle analysis suggested that this growth advantage was the result of increased proliferation as opposed to decreased apoptosis. These in vitro effects of AML1a are broadly in agreement with results obtained by forced expression of AML1a in myeloid cell lines in which granulocytic differentiation was blocked, and this blockade was accompanied by uncompromised cell growth [26] . Most remarkably, AML1a-transduced BM cells were able to expand in a simple culture with SCF and IL3, with immature (c-kit þ lin À ) cells proliferating vigorously yet retaining the ability to produce terminally differentiated myelomonocytic cells in vitro and giving rise to short-term multilineage engraftment in vivo. These extended in vitro cultures established by AML1a-transduced cells thus recapitulate many aspects of hematopoiesis, retaining multipotency in a manner reminiscent of human CD34 þ cells programmed to express the AML1-ETO oncoprotein [49] . Both AML1a and AML1-ETO are thought to interfere with AML1b/c, and possibly also AML2 and AML3, in a dominantnegative fashion, either by directly competing for AMLbinding sites on DNA or by sequestering subunit b of core binding factor (CBFb), an obligate subunit required for binding of AML proteins to DNA [3] . Thus comparison of the results obtained with our AML1a mice to those reported for AML1-ETO and Aml1-targetted animals should be informative with respect to understanding physiological and pathological AML1 activities. Like AML1a animals, ''haploinsufficient''
Aml1
þ/À mice also exhibit increased CFU-GM and CFU-mix, but unlike AML1a mice, the size of colonies generated is unaffected [50] . BM cells of the Aml1 þ/À mice exhibit increased competitiveness accompanied by a nearly doubled frequency of immature hematopoietic stem and progenitors as assessed in CAFC assays [50] . The KSL fraction is increased in the BM hematopoietic cells are defective in competitive repopulation capacity [8] . Mice reconstituted with AML1a-transduced cells did not show appreciably inhibited myeloid differentiation, in contrast to mice reconstituted with hematopoietic cells retrovirally transduced with AML1-ETO [51, 52] . These findings imply that while some aspects associated with forced AML1a expression mimic reduced dosage, although not complete loss, of Aml1, AML1a confers unique effects on stem and progenitor cell properties that cannot be achieved by reducing the dosage of the Aml1 gene or by expression of the AML1-ETO oncoprotein. Of note here also are our preliminary results obtained with a mutant of AML1 (AML1R139G), which can sequester CBFb but cannot bind DNA [53] . Like AML1a, AML1R139G-transduced cells exhibited delayed granulocytic differentiation in vitro. Unlike AML1a, AML1R139G-transduced cells did not produce longterm cultures in vitro and did not contribute to long-term hematopoiesis in vivo (ST, unpublished data). Thus, the ability of AML1a to bind DNA appears crucial for cell expansion, thereby further emphasising that AML1a is not a simple antagonist of AML1b/c or AML2/AML3, but rather exerts distinct effects on hematopoietic cells by virtue of its DNA-binding activity. Although we have in this study concentrated on the role of AML1a, the observation that AML1b can abrogate engraftment, presumably through enhancing granulocytic differentiation, is of interest and perhaps at first glance surprising. However it is now well documented that transcription factor effects are highly dose sensitive. Aml1 is itself a case in point [54] , and GATA-2 [55, 56] , PU1 [57] , and OCT4 [58] provide additional examples. Recent modelling approaches [59] (S. Huang and TE, unpublished data) are starting to illuminate how dosesensitive bi-stable switches can be created as a result of the transcriptional motifs (coherent and incoherent feedforward motifs, crossantagonistic motifs, and the like) adopted by transcription factors. While such dynamic models and the genetic regulatory networks on which they are based [60] do not as yet include Aml1, the fact that Aml1is a key regulator of granulocyte/monocyte-affiliated growth factor receptors as well as transcription factors provides a plausible framework for understanding how increasing its expression could lead to enhanced differentiation at the expense of self-renewal. In light of the AML1a activities highlighted by our experiments, it is intriguing that AML1a transcripts are evident in selected samples of leukaemia [23] . AML1 mutants devoid of the carboxyl-terminal portion of the molecule, and thereby structurally resembling AML1a, are also found in BM cells of some patients with myelodysplastic syndrome and myeloid leukaemia [27] [28] [29] . Collectively, AML1a or diseaseassociated AML1a-like AML1 molecules could be implicated in increased proliferation or competitiveness at key stages of hematopoietic differentiation. Further analysis of the mechanisms involved will be of therapeutic interest in the context of hematopathology and may inform attempts to expand transplantable hematopoietic stem/progenitor cells for cell therapy. Of particular interest as a stem cell source is cord blood. It is widely available through cord-blood banks, is applicable across human leukocyte antigen mismatches, and carries low risks of infectious disease transmission [61] . Despite these merits, slow engraftment and limited cell numbers contained in a given umbilical cord increases the likelihood of serious infectious complications and limits widespread application to adult patients. Modest expansion of stem and progenitor cells would be expected to circumvent these drawbacks [62] , and thus AML1a-mediated mechanisms may therefore prove useful in the facilitation of transplantation therapeutics. Our experiments on human cord blood cells support this view. We have shown at the RNA level that AML1a is predominantly expressed within the primitive CD34 [19] , could be considered. In any event, our results identify AML1a as one of the few molecules [19] with the capacity for increasing the engraftment potential of hematopoietic stem and progenitor cells. In summary, our findings are of interest with respect to both the physiological and pathological roles of AML1 isoforms and have clear implications for hematopoietic cell transplantation.
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Editors' Summary
Background. Blood contains red blood cells (which carry oxygen round the body), platelets (which help the blood to clot), and white blood cells (which fight off infections). All these cells, which are regularly replaced, are derived from hematopoietic stem cells, blood-forming cells present in the bone marrow. Like all stem cells, hematopoietic stem cells selfrenew (reproduce themselves) and produce committed progenitor cells, which develop into mature blood cells in a process called hematopoiesis. Many proteins control hematopoiesis, some of which are called transcription factors; these factors bind to DNA through their DNAbinding domain and then control the expression of genes (that is, how DNA is turned into proteins) through particular parts of the protein (their transcription regulatory domains). An important hematopoietic transcription factor is AML1-a protein first identified because of its involvement in acute myelogenous leukemia (AML, a form of blood cancer). Mutations (changes) in the AML1 gene are now known to be present in other types of leukemia, which are often characterized by overproliferation of immature blood cells.
Why Was This Study Done? Because of AML19s crucial role in hematopoiesis, knowing more about which genes it regulates and how its activity is regulated could provide clues to treating leukemia and to improving hematopoietic cell transplantation. Many cancer treatments destroy hematopoietic stem cells, leaving patients vulnerable to infection. Transplants of bone marrow or cord blood (the cord that links mother and baby during pregnancy contains peripheral blood stem cells) can replace the missing cells, but cord blood in particular often contains insufficient stem cells for successful transplantation. It would be useful, therefore, to expand the stem cell content of these tissues before transplantation. In this study, the researchers investigated the effect of AML1 on self-renewal and differentiation of hematopoietic stem and progenitor cells in the laboratory (in vitro) and in animals (in vivo). In particular, they have asked how two isoforms (closely related versions) of AML1 affect the ability of these cells to grow and differentiate (engraft) in mice after transplantation.
What Did the Researchers Do and Find? The researchers artificially expressed AML1a and AML1b (both isoforms contain a DNA binding domain, but only AML1b has transcription regulatory domains) in mouse hematopoietic stem and progenitor cells and then tested the cells' ability to engraft in mice. AML1a-expressing cells engrafted better than unaltered cells and outgrew unaltered cells when transplanted as a mixture. AML1b-expressing cells, however, did not engraft. In vitro, AML1a-expressing cells grew more than AML1b-expressing cells, whereas differentiation was promoted in AML1b-expressing cells. To investigate whether the isoforms have the same effects in human cells, the researchers measured the amount of AML1a and AML1b mRNA (the template for protein production) made by progenitor cells in human cord blood. Although AML1b (together with AML1c, an isoform with similar characteristics) mRNA predominated in all the progenitor cell types, the relative abundance of AML1a was greatest in the stem and progenitor cells. Furthermore, forced expression of AML1a in these cells improved their ability to divide in vitro and to engraft in mice.
What Do These Findings Mean? These findings indicate that AML1a expression increases the self-renewal capacity of hematopoietic stem and progenitor cells and consequently improves their ability to engraft in mice, whereas AML1b expression encourages the differentiation of these cell types. These activities are consistent with the expression patterns of the two isoforms in normal hematopoietic cells and in leukemic cellsthe mutated AML made by many leukemic cells resembles AML1a.
Because the AML1 isoforms were expressed at higher than normal levels in these experiments, the physiological relevance of these findings needs to be confirmed by showing that normal levels of AML1a and AML1b produce similar results. Nevertheless, these results suggest that manipulating the balance of AML1 isoforms made by hematopoietic cells might be useful clinically. In leukemia, a shift toward AML1b expression might slow the proliferation of leukemic cells and encourage their differentiation. Conversely, in cord blood transplantation, a shift toward AML1a expression might improve patient outcomes by expanding the stem and progenitor cell populations.
Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed. 0040172.
Wikipedia has pages on hematopoiesis and hematopoietic stem cells (note: Wikipedia is a free online encyclopedia that anyone can edit; available in several languages) The US National Cancer Institute has a fact sheet on bone marrow and peripheral blood stem cell transplantation (in English and Spanish) and information for patients and professionals on leukemia (in English) The American Society of Hematology provides patient information about blood diseases, including information on bone marrow and stem cell transplantation
